A Phase I study to evaluate the safety and efficacy of L19IL2 in combination with ruxolitinib in patients with advanced solid tumors.

2025-522243-17-00 Protocol PH-L19IL2CORK-01/25 Human pharmacology (Phase I) - Other Authorised, recruitment pending

Status Authorised, recruitment pending · 1 EU/EEA countries · 1 sites · Protocol PH-L19IL2CORK-01/25

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Authorised, recruitment pending
Participants planned 96
Countries 1
Sites 1

Advanced solid tumors, specifically: • metastatic clear cell renal carcinoma • proficient mismatch repair / microsatellite stable (pMMR/MSS), BRAF-V600E-mutant negative colorectal carcinoma • locally advanced or metastatic pancreatic adenocarcinoma

Key facts

Sponsor
Philogen S.p.A.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Decision date (initial)
2025-12-22
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Advanced solid tumors, specifically: • metastatic clear cell renal carcinoma • proficient mismatch repair / microsatellite stable (pMMR/MSS), BRAF-V600E-mutant negative colorectal carcinoma • locally advanced or metastatic pancreatic adenocarcinoma

VersionLevelCodeTermSystem organ class
28.0 LLT 10007116 Cancer of skin (excl melanoma) 10029104

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Philogen S.p.A.

Sponsor organisation
Philogen S.p.A.
Address
Piazza La Lizza 7
City
Siena
Postcode
53100
Country
Italy

Scientific contact point

Organisation
Philogen S.p.A.
Contact name
Claudio Nanni

Public contact point

Organisation
Philogen S.p.A.
Contact name
Federica Bastioli

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Italy Authorised, recruitment pending 96 1
Rest of world 0

Investigational sites

Italy

1 site · Authorised, recruitment pending
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
UOC Phase 1, Largo Francesco Vito 1, 00168, Rome

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-08-08 Italy Acceptable
2025-12-18
2025-12-22
2 SUBSTANTIAL MODIFICATION SM-1 2026-01-30 Italy Acceptable
2026-04-16
2026-04-20